Skip to main content
. 2021 Dec 4;11(12):3779–3790. doi: 10.1016/j.apsb.2021.11.022

Figure 1.

Figure 1

PEG-ASNase in mice leads to fatty liver and liver injury. (A) Oil red O (ORO) and H&E staining of liver samples collected from mice receiving 1500 U/kg of PEG-ASNase (Days 1, 3, 5 and 7) indicate the development of hepatic steatosis relative to controls. (B) Mice receiving PEG-ASNase had ∼5-, 4-, and 3-fold higher triglyceride (TG) concentrations at 3, 5, and 7 days after treatment, respectively. (C–F) Plasma total/direct bilirubin, alanine transaminase (ALT), and aspartate transaminase (AST) levels were higher in PEG-ASNase-treated mice compared to controls. Data is the mean ± SD with statistical significance indicated as ∗∗∗∗ for P < 0.0001, ∗∗∗ for P < 0.001, ∗∗ for P < 0.01, and ∗ for P < 0.05. Data from n ≥ 30 mice. Scale bar in (A) indicates 50 μm.